COP:XETRA-CompuGroup Medical SE & Co. KGaA (EUR)

COMMON STOCK | Health Information Services | XETRA

Last Closing Price

EUR 71.15

Change

0.00 (0.00)%

Market Cap

EUR 3.71B

Volume

0.04M

Avg Analyst Target

EUR 76.25 (+7.17%)

Avg User Target

EUR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

CompuGroup Medical SE & Co. KGaA develops and sells software and information technology solutions for the healthcare sector worldwide. It operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS). The AIS segment provides practice management software and electronic medical records for registered physicians, medical care centers, and physicians networks, as well as offers supplementary Internet and intranet solutions. The PCS segment provides administrative and billing-related software applications for pharmacies. Its software solution provides information and decision support to manage various aspects of supply chain for medication. The HIS segment provides clinical and administrative solutions for the inpatient sector. This segment serves acute care hospitals, rehabilitation centers, social services, multi-location hospital networks and regional care organizations, and medical laboratories. The CHS segment provides IT security services, data-based product offers, software interface for sharing of information, clinical decision-making support, and medication and treatment databases for healthcare service providers, as well as digital healthcare stock, consumer portals, and mobile apps. This segment also offers security solutions for healthcare providers. It serves pharmaceutical companies, health insurance companies, and other healthcare IT companies and consumers. The company was formerly known as CompuGroup Medical SE and changed its name to CompuGroup Medical SE & Co. KGaA in June 2020. CompuGroup Medical SE & Co. KGaA was founded in 1987 and is headquartered in Koblenz, Germany. Address: Maria Trost 21, Koblenz, Germany, 56070

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-16 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NXU:XETRA Nexus AG

N/A

EUR1.15B 70.43 28.07
AJ91:XETRA DocCheck AG

N/A

EUR0.13B 13.74 6.82
M3V:XETRA MeVis Medical Solutions AG

N/A

EUR0.06B 11.33 10.28
IS8:XETRA ifa systems AG

N/A

EUR0.02B 1,450.00 11.88
NMI:XETRA Aladdin Healthcare Technologie..

N/A

EUR2.35M N/A N/A

ETFs Containing COP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.48% 33% F 7% F
Dividend Return 0.64% 67% D+ 18% F
Total Return -8.84% 33% F 7% F
Trailing 12 Months  
Capital Gain -9.54% 33% F 6% F
Dividend Return 0.64% 67% D+ 14% F
Total Return -8.90% 33% F 6% F
Trailing 5 Years  
Capital Gain 77.88% 60% D- 74% C
Dividend Return 4.25% 75% C 17% F
Total Return 82.13% 60% D- 74% C
Average Annual (5 Year Horizon)  
Capital Gain 16.29% 67% D+ 84% B
Dividend Return 0.64% 60% D- 53% F
Total Return 16.93% 67% D+ 84% B
Risk Return Profile  
Volatility (Standard Deviation) 22.80% 83% B 32% F
Risk Adjusted Return 74.25% 83% B 83% B
Market Capitalization 3.71B 100% A+ 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 54.02 60% D- 20% F
Price/Book Ratio 6.23 33% F 21% F
Price / Cash Flow Ratio 24.73 33% F 20% F
EV/EBITDA 20.26 40% F 24% F
Management Effectiveness  
Return on Equity 12.31% 50% F 57% F
Return on Invested Capital 9.06% 33% F 68% D+
Return on Assets 4.65% 50% F 65% D
Debt to Equity Ratio 73.62% 25% F 37% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.86 33% F 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.